Drug Search Results
More Filters [+]

177Lu-DOTA-EB-TATE

Alternative Names: 177Lu-DOTA-EB-TATE, EBTATE
Latest Update: 2024-09-11
Latest Update Note: News Article

Product Description

Mechanisms of Action: Imaging Agent

Novel Mechanism: No

Modality: Diagnostic Agent

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Molecular Targeting Technologies
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for 177Lu-DOTA-EB-TATE

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Neuroendocrine Tumors

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MTTI-EBT-001

P1

Recruiting

Neuroendocrine Tumors

2024-12-31

44%

Recent News Events